Multiple clinical trials have been conducted in recent years demonstrating that the addition of endostatin to the standard treatment of advanced NSCLC significantly increases the overall survival (OS) and the progression-free survival time (PFS) of patients in locally advanced [41,42,43,44,45,46,47,48,49,50,51] or metastatic disease [43,49,50,51,52,53,54]. Here, COL18A1 is linked to non-small cell lung carcinoma.